No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 33 of the 40 quarters in the window, leaving 7 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Phio Pharmaceuticals Corp. (PHIO) stock was $0.99 as of Oct 6, 2026, 4:00 PM EDT, up 0.34% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -58.4% · 3-year avg -57.7%/yr · 5-year avg -65.7%/yr
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies.
Biotechnology · King of Prussia, PA
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
-0.36
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.36
vs Estimate
$-0.36
Revenue
$0.00
vs Estimate
$0.00
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1PHIO | $11.55M | $0.99 | +0.34% | -58.36% | -65.73% | -68.44% | N/A |
| 2CABR | $11.46M | $1.26 | +11.50% | -69.29% | N/A | N/A | vs PHIO |
| 3KPRX | $11.39M | $2.57 | +1.58% | -7.96% | -67.06% | -55.97% | vs PHIO |
| 4IRIX | $11.77M | $0.68 | -1.45% | -42.35% | -38.13% | -26.14% | vs PHIO |
| 5LSTA | $11.29M | $1.24 | -1.59% | -49.83% | -40.75% | -32.84% | vs PHIO |
| 6BFRI | $11.93M | $0.93 | +4.61% | -16.67% | N/A | N/A | vs PHIO |
forward FY estimate
N/A
Consensus Rating
Based on 1 analyst
Average Price Target
$14.00
+1307.9% upside
Low
$14.00
Current
$0.99
High
$14.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.37 | $-0.36 | $-0.35 | 2 |
| Quarter ending Dec 2026 | $-0.39 | $-0.39 | $-0.37 | 2 |
| Quarter ending Mar 2027 | $-0.13 | $-0.13 | $-0.13 | 1 |
| Quarter ending Jun 2027 | $-0.09 | $-0.09 | $-0.09 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.46 | $-1.45 | $-1.42 | 2 |
| FY 2027 | $-0.77 | $-0.61 | $-0.45 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2027 | $0.00 | $0.00 | $0.00 | 0 |
